Hypothesis: ALN-TTRsc04 rapidly knocks down serum TTR and is well tolerated. Aims: Describe safety, pharmacokinetics, and pharmacodynamics of single ascending ALN-TTRsc04 doses. Methods: This ongoing, Phase 1, randomized, double-blind, placebo-controlled study (NCT05661916) enrolled healthy ...
作者: $阿里拉姆制药(ALNY)$ALN-TTRsc04 Ph1 SAD 和10月TTR Day的差不多 网页链接 网页链接